Evidence map›Paper›PMID 31295304›Full record

ArticlePloS one2019

Relationship between infarct size and serum uric acid levels during the acute phase of stroke.

Rodrigo Fernández-Gajardo, José Manuel Matamala, Rodrigo Gutiérrez, Prudencio Lozano, Ignacio A Cortés-Fuentes, Camilo G Sotomayor, Gonzalo Bustamante, Juan A Pasten, Gabriel Vargas, Rodrigo Guerrero and 4 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Rodrigo Fernández-GajardoDepartment of Neurological Sciences, Faculty of Medicine, University of Chile, Santiago, Chile.ORCID 0000-0001-9448-2028
José Manuel MatamalaDepartment of Neurological Sciences, Faculty of Medicine, University of Chile, Santiago, Chile.
Rodrigo GutiérrezMolecular and Clinical Pharmacology Program, Institute of Biomedical Sciences, Faculty of Medicine, University of Chile, Santiago, Chile.
Prudencio LozanoDepartment of Neurology, Clínica Santa María, Santiago, Chile.
Ignacio A Cortés-FuentesMolecular and Clinical Pharmacology Program, Institute of Biomedical Sciences, Faculty of Medicine, University of Chile, Santiago, Chile.
Camilo G SotomayorMolecular and Clinical Pharmacology Program, Institute of Biomedical Sciences, Faculty of Medicine, University of Chile, Santiago, Chile.ORCID 0000-0001-6835-6386
Gonzalo BustamanteDepartment of Neurological Sciences, Faculty of Medicine, University of Chile, Santiago, Chile.
Juan A PastenDepartment of Neurology, Clínica Santa María, Santiago, Chile.
Gabriel VargasDepartment of Neurology, Clínica Santa María, Santiago, Chile.
Rodrigo GuerreroDepartment of Neurology, Clínica Santa María, Santiago, Chile.
Pablo ReyesDepartment of Neurological Sciences, Faculty of Medicine, University of Chile, Santiago, Chile.
Gabriel CavadaSchool of Public Health, University of Chile, Santiago, Chile.
Walter FeuerhakeDepartment of Neurological Sciences, Faculty of Medicine, University of Chile, Santiago, Chile.
Ramón RodrigoMolecular and Clinical Pharmacology Program, Institute of Biomedical Sciences, Faculty of Medicine, University of Chile, Santiago, Chile.
Clinica Santa Maria · CLUniversity of Chile · CL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionUric acid has gained considerable attention as a potential neuroprotective agent in stroke during the last decades, however, its role in the pathophysiology of ischemic stroke remains poorly understood. A serial evaluation of uric acid levels during the acute phase of stroke and its association with infarct size on magnetic resonance imaging is lacking.

methodsWe present a cohort study of 31 patients with ischemic stroke who were not candidates for thrombolysis according to current criteria at the time. We performed daily measurements of serum uric acid and total antioxidant capacity of plasma during the first week after symptoms onset and 30 days after. Infarct size was determined in the acute phase by a DWI sequence and the final infarct size with a control MRI (FLAIR) at day 30.

resultsUric acid significantly decreases between days 2 to 6 compared to day 1, after adjustment by sex, age and DWI at diagnosis, with a nadir value at 72h. A mixed model analysis showed a negative association between DWI at diagnosis and uric acid evolution during the first week after stroke. Moreover, multivariable linear regression of uric acid values during follow up on DWI volumes demonstrated that DWI volume at diagnosis is negatively associated with uric acid levels at day 3 and 4. There were no significant associations between total antioxidant capacity of plasma and DWI at diagnosis, or FLAIR at any point. DISCUSSION: Patients with larger infarcts exhibited a significant decrease in serum uric acid levels, accounting for a more prominent reactive oxygen species scavenging activity with subsequent consumption and decay of this antioxidant. The different kinetics of total antioxidant capacity of plasma and serum uric acid levels suggests a specific role of uric acid in the antioxidant response in ischemic stroke.

Indexed as

AntioxidantsFemaleFluorescence Recovery After PhotobleachingHumansLinear ModelsMagnetic Resonance ImagingMaleMiddle AgedStrokeUric AcidAntioxidantsUric Acid

Identifiers

PMID31295304
PMCPMC6622494
OpenAlexW2961978147

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.